Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 23 of 58, showing 10 Applications out of 576 total, starting on record 221, ending on 230

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

221.

ECCT/22/02/02   The Women TAF-FTC Benchmark
    Safety and Pharmacokinetics of TAF-FTC Pre-exposure Prophylaxis in Kenyan Cisgender women   
Principal Investigator(s)
1. Dr. Nelly Rwamba Mugo
Site(s) in Kenya
KEMRI-CCR PHRD Thika
 
18-11-2022 View

222.

ECCT/22/03/05   CHAPATI
    CHildren treated with vincristine: A trial regarding Pharmacokinetics, DNA And Toxicity of targeted therapy In pediatric oncology patients.   
Principal Investigator(s)
1. FESTUS MUIGAI NJUGUNA
Site(s) in Kenya
Moi Teaching and Referral Hospital
 
25-10-2022 View

223.

ECCT/22/08/01   GBT Open Label inclacumab Ph3
    An Open-Label Extension Study to Evaluate the Long-Term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial   
Principal Investigator(s)
1. Prof Jessie N Githanga
2. Bernhards Ragama Ogutu
3. Fredrick Asirwa Chite
4. Videlis N Nduba
Site(s) in Kenya
1. Gertrude’s Children’s Hospital (Nairobi City county)
2. Strathmore University Medical Centre (Nairobi City county)
3. International Cancer Institute (ICI)-Eldoret (Uasin Gishu county)
4. KEMRI/CRDR (Nairobi City county)
5. KEMRI Siaya Clinical Research Annex (Siaya county)
 
19-10-2022 View

224.

ECCT/22/07/01   GBT021601-021 Study
    A Phase 2/3 Randomized, Multicenter Study of GBT021601 Administered Orally to Participants with Sickle Cell Disease and an Open-Label Pharmacokinetics Study in Pediatric Participants with Sickle Cell Disease   
Principal Investigator(s)
1. Jessie Nyokabi Githanga
2. Berhnards Ragama Ogutu
3. Videlis Nduba
4. Berhnards Ragama Ogutu
Site(s) in Kenya
1. Gertude\'s Children\'s Hospital (Nairobi City county)
2. CENTER FOR RESEARCH IN THERAPEUTIC SCIENCES-STRATHMORE UNIVERSITY MEDICAL CENTER (CREATES (Nairobi City county)
3. / KENYA MEDICAL RESEARCH INSTITUTE- CENTER FOR RESPIRATORY DISEASE RESEARCH(CRDR) (Nairobi City county)
4. KENYA MEDICAL RESEARCH INSTITUTE- SIAYA COUNTY REFERAL HOSPITAL (Siaya county)
 
17-10-2022 View

225.

ECCT/22/05/01   VICTORION-2 PREVENT
    A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with   established cardiovascular disease   
Principal Investigator(s)
1. Anthony Gikonyo
2. ELIJAH SAMMY NYAINDA OGOLA
Site(s) in Kenya
1. The Karen Hospital (Nairobi City county)
2. Centre for research in Therapeutic Sciences (CREATES (Nairobi City county)
 
05-10-2022 View

226.

ECCT/22/09/03   SINGLE DOSE VERSUS EXTENDED DO
    EFFECTIVENESS OFSINGLE-DOSE ANTIBIOTIC USE IN ELECTIVE CAESAREANSECTION IN PREVENTION OF SURGICAL SITE INFECTION AT JARAMOGI    OGINGA ODINGA TEACHING AND REFERRAL HOSPITAL, KISUMU COUNTY,KENYA: A RANDOMIZED CONTROL TRIAL.   
Principal Investigator(s)
1. STEVEN ODHIAMBO JUMA
Site(s) in Kenya
JARAMOGI OGINGA ODINGA TEACHING AND REFERRAL HOSPITAL
 
26-09-2022 View

227.

ECCT/22/05/02   BREATHER Plus
        A randomised open-label 2-arm, 96-week trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily dolutegravir/tenofovir-based triple ART in virologically suppressed HIV-infected adolescents aged 12 to 19 years of age in sub-Saharan Africa   
Principal Investigator(s)
1. Abraham Siika
Site(s) in Kenya
Moi University Clinical Research Centre
 
25-09-2022 View

228.

ECCT/21/09/01   Kuwa Free! - Live free!
    Co-benefits of co-delivery of long-acting antiretrovirals and contraceptives   
Principal Investigator(s)
1. Rena Patel
2. Edwin Were
Site(s) in Kenya
Moi Teaching and Referral Hospital
 
16-09-2022 View

229.

ECCT/22/03/06   Sickle Cell Disease
    A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Characterize the Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients with Sickle Cell Disease   
Principal Investigator(s)
1. Janet Oyieko
2. Fredrick Chite Asirwa
3. Bernhards Ogutu
Site(s) in Kenya
1. Kombewa Clinical Research Centre (Kisumu county)
2. Victoria Biomedical Research institute (Kisumu county)
3. International Cancer Centre (Uasin Gishu county)
4. CREATES - Strathmore University Medical Centre (Nairobi City county)
 
15-09-2022 View

230.

ECCT/22/06/02   Mitapivat - AG348-C-020
    A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease.   
Principal Investigator(s)
1. Lucas Otieno Tina
2. Bernhards Ragama Ogutu
3. Prof Jessie N Githanga
4. Videlis N Nduba
5. Janet N/A Oyieko
6. Allan Godfrey Otieno
Site(s) in Kenya
1. Victoria Biomedical Research Institute (Kisumu county)
2. Strathmore University Medical Centre (Nairobi City county)
3. KEMRI/CRDR (Nairobi City county)
4. KEMRI Siaya Clinical Research Annex (Siaya county)
5. Gertrude’s Children’s Hospital (Nairobi City county)
6. KEMRI Kondele Children\'s Hospital (Kisumu county)
7. Kombewa Clinical Research Centre (Kisumu county)
 
06-09-2022 View